Roche announced that it will enter into a strategic alliance with Singapore’s scientific and medical institutions to set up a major new translational research hub in Singapore.

This “Hub for Translational Medicine” aims to enhance the understanding of how scientific advances from preclinical research can be transferred in practice to patients. Bringing together world-class expertise from Singapore’s scientific and medical research institutions with Roche’s significant capability in translational medicine and clinical development, this new centre will focus on expanding knowledge of disease biology to develop new personalised treatment approaches.

“Singapore’s research institutions offer outstanding scientific excellence combined with state-of-the-art translational medicine facilities,” said Jean-Jacques Garaud, Global Head of Roche Pharma Research and Early Development. “The powerful combination of intellectual and technological capabilities together with outstanding government commitment at the heart of this collaboration will provide a unique opportunity to drive personalised healthcare.”

With an investment of 100 million Swiss Francs, the Hub for Translational Medicine will initially employ around 30 leading scientists.